Orexo Reports Phase I Trial Results For OX219, A Novel Sublingual Tablet Formulation For The Treatment Of Opioid Dependence

by Dr. Rich on September 5, 2011

Orexo AB (STO:ORX) announces successful completion of the initial pharmacokinetic trial in the OX219 project. In the comparative bioavailability study, the OX219 buprenorphine/naloxone sublingual tablet formulation demonstrated favourable profiles compared to the comparator Suboxone®, which is the market leading product for treatment of opioid dependence. Global value of the opioid dependence market today is approximately US$ 1.4 billion. Based on the positive results, Orexo will be meeting with the FDA during Q1-2011 to discuss the development program for OX219… (Source: Health News from Medical News Today)

Previous post:

Next post: